Executive SummaryFormer FDA Generic Drug Division Director retiring from the agency after 24 years of service. Seife's departure follows his reassignment outside the division in May, after evidence came to light that division reviewers had accepted illegal gratuities from several generic drug companies. He has been on special assignment to the Office of Drug Evaluation I. During his tenure at FDA, Seife served as director of Generic Drug Monographs and generic staff (1972-84), deputy director for Medical Activities and acting director, Scientific Evaluation Office (1970-72), and acting director and director of the Cardio-Renal Division (1967-68).
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.